NCT03583528 2025-06-13
DOTATOC PET/CT for Imaging NET Patients
British Columbia Cancer Agency
Active not recruiting
Clinical Trials
10 trialsNCT00442533 2023-04-03
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Radio Isotope Therapy of America
Phase 2/3 Completed
NCT02431715 2023-02-21
18F-FDOPA PET in Neuroendocrine Tumours
British Columbia Cancer Agency
No longer available
NCT04017104 2021-01-26
Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging
British Columbia Cancer Agency
Unknown
NCT02441062 2020-12-21
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
University of Iowa
Phase 2 Completed
NCT02177773 2019-11-12
DOTA-TOC
University of California, San Francisco
Phase 1/2 Terminated
NCT00947167 2017-03-03
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Stanford University
Phase 2 Terminated
NCT00339131 2011-10-12
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
Molecular Insight Pharmaceuticals, Inc.
Phase 1 Completed
NCT01373736 2011-06-15
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
Vancouver Coastal Health
Phase 3 Unknown
NCT00314925 2010-02-25
Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features
Neotropix
Phase 1 Unknown